Shares of Arbutus Biopharma Corp. (NASDAQ:ABUS) were down 2.3% during trading on Wednesday . The stock traded as low as $3.75 and last traded at $3.87, with a volume of 74,671 shares. The stock had previously closed at $3.96.

Several analysts recently commented on ABUS shares. Leerink Swann reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Arbutus Biopharma Corp. in a report on Thursday, May 5th. William Blair started coverage on Arbutus Biopharma Corp. in a report on Friday, August 19th. They issued a “buy” rating and a $7.00 price objective for the company. Zacks Investment Research raised Arbutus Biopharma Corp. from a “sell” rating to a “hold” rating in a report on Thursday, August 18th. Chardan Capital raised Arbutus Biopharma Corp. from a “sell” rating to a “neutral” rating and set a $3.25 price objective for the company in a report on Thursday, June 16th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of Arbutus Biopharma Corp. in a report on Wednesday, May 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $9.39.

The firm’s 50-day moving average is $4.00 and its 200-day moving average is $3.98. The company’s market cap is $207.68 million.

Arbutus Biopharma Corp. (NASDAQ:ABUS) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.36. Analysts anticipate that Arbutus Biopharma Corp. will post ($3.35) EPS for the current fiscal year.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.